Here's Why Cara Therapeutics Rose 9.6% in August

Cara Therapeutics (NASDAQ: CARA), a clinical-stage biotech focused on drugs that relieve pain, rose by nearly 10% during August, according to data from S&P Global Market Intelligence. The jump was caused by management;s sharing some upbeat news with investors during its second-quarter earnings report.

Here's a review of the financial highlights from the second quarter, as well as a few key upcoming milestones:

While Cara's stock rose sharply in response to this earnings report, it gradually fell back to earth in the following weeks. However, Cara ended August on a high note, after the company announced that it would be presenting clinical data at two upcoming medical conferences. That news was apparently enough to get traders interested in the stock once again.

Source: Fool.com